Originally posted in Cystic Fibrosis News From Medical News Today

Today the U.S. House of Representatives passed the “Improving Access to Clinical Trials Act” (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations. The bill, which passed the Senate Aug. 5, now goes to President Obama’s desk for his signature. He is expected to sign it…

Originally posted in Cystic Fibrosis News From Medical News Today

The U.S. House of Representatives passed the “Improving Access to Clinical Trials Act” (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations. The bill, which passed the Senate Aug. 5, now goes to President Obama’s desk for his signature. He is expected to sign it…

Originally posted in Cystic Fibrosis News From Medical News Today

PTC Therapeutics, Inc. (PTC) announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF)…

Originally posted in Cystic Fibrosis News From Medical News Today

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 – 22, 2010 in Barcelona, Spain…

Originally posted in Cystic Fibrosis News From Medical News Today

The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation…

Originally posted in Cystic Fibrosis News From Medical News Today

Three University of Massachusetts Amherst scientists have received a four-year, $1.2 million EUREKA grant from the U.S. National Institutes of Health (NIH) to study folding and misfolding of secretory proteins in the cell’s protein factory, the endoplasmic reticulum, where misfolding can lead to diseases such as cystic fibrosis and liver cirrhosis…

Originally posted in Journal of Cystic Fibrosis

While the determination of exercise capacity is viewed as clinical best practice in cystic fibrosis (CF), its measurement using a cardiopulmonary exercise test (CPET) remains as somewhat of a mystery for many CF clinicians. Two studies in the current issue (of the Journal of Cystic Fibrosis) highlight the use of exercise testing in CF clinical practice. The role of retained exercise capacity (VO2max) and levels of physical activity in CF in maintaining health status is compelling. Using an accelerometer to determine levels of physical activity, Hebestreit et al. found that more physically active CF patients had best preserved VO2max, FEV1 and nutritional status. These results are supported by a more recent review by Wilkes and colleagues who reported that children with CF with increased activity demonstrated a reduced decline in pulmonary function.